Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EXACT SCIENCES CORP Regulatory Filings 2011

Dec 6, 2011

30597_rns_2011-12-06_c4146164-8a10-49d2-bb06-010838fe6e55.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

*Issuer Free Writing Prospectus dated December 5, 2011*

*Filed Pursuant to Rule 433*

*Registration No. 333- 168907*

*(Relating to the Preliminary Prospectus Supplement dated December 5, 2010*

*and the Prospectus dated September 7, 2010)*

FINAL TERM SHEET

Issuer Exact Sciences Corporation (NASDAQ: EXAS)
Underwriters Robert W. Baird & Co. Incorporated, Sole Book-Running Manager William Blair & Company, L.L.C., Co-Manager
Common stock offered by Exact 3,125,000 shares
Over-allotment option 468,750 shares
Common stock to be outstanding after this offering 56,035,773 shares (56,504,523 if the underwriters’ over-allotment option is exercised in full)
Public offering price $8.00 per share.
Net proceeds to Exact $23.6 million ($27.1 million if the underwriters’ over-allotment option is exercised in full), after deducting the underwriting discount ($0.40 per share) and estimated offering expenses payable by us
Pricing date December 5, 2011
Closing date On or about December 9, 2011
Dilution Net tangible book value per share as of September 30, 2011: $1.22 Net tangible book value per share after the offering: $1.57 ($1.62 if the underwriters’ over-allotment option is exercised in full) Increase in per share net tangible book value per share attributable to the offering: $0.35 ($0.40 if the underwriters’ over-allotment option is exercised in full) Dilution per share to new investors: $6.43 ($6.38 if the underwriters’ over-allotment option is exercised in full)

The number of shares of common stock outstanding used in the above disclosures is based on 52,910,773 shares outstanding as of September 30, 2011, qualified as stated in the preliminary prospectus supplement.

We have filed a registration statement, a prospectus and a preliminary prospectus supplement with the Securities and Exchange Commission, or SEC, for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement and related prospectus as well as the other documents we have filed with the SEC for more complete information about us and this offering. You may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, we or the underwriters for this offering will arrange to send you the preliminary prospectus supplement (or, if then available, the final prospectus supplement) and related prospectus if you request it from the offices of Robert W. Baird & Co. Incorporated, 777 E. Wisconsin Ave., 28th Floor, Milwaukee, WI 53202-5391, or by calling 1-800-792-2413. The following information supplements and updates the information contained in the preliminary prospectus supplement and the related prospectus.

SEQ.=1,FOLIO='',FILE='C:\JMS\106756\11-31071-4\task4997438\31071-4-be.htm',USER='106756',CD='Dec 6 18:32 2011'